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Abstract
Background
In 2014–2015, we assessed favipiravir tolerance and efficacy in patients with Ebola virus
(EBOV) disease (EVD) in Guinea (JIKI trial). Because the drug had never been used
before for this indication and that high concentrations of the drugs were needed to achieve
antiviral efficacy against EBOV, a pharmacokinetic model had been used to propose rele-
vant dosing regimen. Here we report the favipiravir plasma concentrations that were
achieved in participants in the JIKI trial and put them in perspective with the model-based
targeted concentrations.
Methods and findings
Pre-dose drug concentrations were collected at Day-2 and Day-4 of treatment in 66 patients
of the JIKI trial and compared to those predicted by the model taking into account patient’s
individual characteristics. At Day-2, the observed concentrations were slightly lower than
the model predictions adjusted for patient’s characteristics (median value of 46.1 versus
54.3 μg/mL for observed and predicted concentrations, respectively, p = 0.012). However,
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the concentrations dropped at Day-4, which was not anticipated by the model (median val-
ues of 25.9 and 64.4 μg/mL for observed and predicted concentrations, respectively,
p<10−6). There was no significant relationship between favipiravir concentrations and EBOV
viral kinetics or mortality.
Conclusions
Favipiravir plasma concentrations in the JIKI trial failed to achieve the target exposure
defined before the trial. Furthermore, the drug concentration experienced an unanticipated
drop between Day-2 and Day-4. The origin of this drop could be due to severe sepsis condi-
tions and/or to intrinsic properties of favipiravir metabolism. Dose-ranging studies should be
performed in healthy volunteers to assess the concentrations and the tolerance that could
be achieved with high doses.
Trial registration
ClinicalTrials.gov NCT02329054
Author summary
In 2014–2015, the JIKI trial was conducted in Guinea to test favipiravir tolerance and effi-
cacy in patients with Ebola virus disease (EDV). The main results of the trial were previ-
ously published without drug concentrations which were not available at the time of
publication. The purpose of this study was to report favipiravir concentrations achieved in
participants in the JIKI trial and to compare them with the targeted concentrations. We
analyzed drug concentrations obtained at Day-2 and Day-4 and compared them to the
targeted concentrations. At Day-2, favipiravir concentrations were significantly below but
still close to the targeted concentration. At Day-4, a significant and unanticipated drop of
concentrations as compared to Day-2 was observed. The origin of the lower-than-targeted
concentrations and the unexpected drop could be due to severe sepsis conditions and/or
to intrinsic properties of favipiravir metabolism. No significant correlation was found
between the drug exposure and the virological response, indicating that it is possible that
the favipiravir concentrations in the JIKI trial were not sufficient to strongly inhibit the
viral replication. These findings suggest the necessity of performing dose-ranging studies
with high doses of favipiravir in healthy volunteers to inform any further development of
favipiravir for treatment of EVD.
Introduction
The 2014–2016 Ebola virus disease (EVD) outbreak in West Africa has been the deadliest
occurrence of the disease since its discovery in 1976. Between January 2014 and June 2016, the
World Health Organization reported 28,616 EVD cases, of which 11,310 were fatal [1]. In Sep-
tember 2014, at the peak of the outbreak, World Health Organization launched a fast-track
process to identify potential anti-Ebola drugs and established three criteria for a drug to be
acceptable as a candidate for clinical trials, namely i) availability of safety data in humans ii)
evidence from preclinical studies of in vivo efficacy against Ebola virus (EBOV) iii) sufficient
drug supply.
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Favipiravir, a RNA polymerase inhibitor, approved in Japan to treat non complicated influ-
enza infection, met all three criteria [2]. First the drug demonstrated antiviral activity against
EBOV both in vitro (with a drug EC50 found between 10.8 μg/mL and 63 μg/mL) and in vivo
in mice models [3,4]. Second it had been already safely administered to more than 2000
healthy volunteers and patients worldwide [5] and its pharmacokinetics (PK) was therefore
well characterized for the influenza dosing. Briefly, the drug is a small and relatively hydro-
philic molecule, with a protein bound fraction of 54% and a distribution volume between 15
and 20 liters [6]. Administered orally, the drug is rapidly absorbed with a tmax ranging from
0.5 to 1 hour and a bioavailability close to 100% [6]. The main elimination pathway involves
hepatic metabolism by aldehyde oxidase, and marginally xanthine oxidase, producing a hydro-
philic and inactive metabolite M1, which is eliminated in the urine [6]. Favipiravir inhibits
aldehyde oxidase, leading to time- and dose-dependent pharmacokinetics [6].
In November 2014, our group decided to perform a historically-controlled, single-arm
proof-of-concept trial to assess the tolerance and efficacy of favipiravir in patients with
EVD in Guinea (JIKI trial) [7]. Launching an emergency trial in the midst of such an histor-
ical outbreak posed many human, logistical, ethical and scientific challenges. Among those
was the choice of the dosing regimen to be used against EBOV, which has been explained
prior to the trial implementation [8]. In brief the dosing regimen was found such that it
achieves safely and rapidly free average concentration comparable to that obtained in mice
successfully treated while maintaining free minimal concentrations higher than the drug
EC50. Because the pharmacokinetics is nonlinear, the search for an optimal dosing regimen
was based on a pharmacokinetic model developed by the manufacturer. Using this model a
dosing regimen of 1,200 mg every twelve hours was proposed for the maintenance dose,
with a loading dose of 6,000 mg (2,400; 2,400; 1,200 mg) on the first day. This dosing regi-
men was predicted to achieve stable concentrations after 48 hours, with median total trough
(pre-dose) and average concentrations in plasma of 57.0 and 83.3 μg/mL, respectively [8].
One important aspect regarding this model is that it had been developed using data col-
lected in studies in which the highest maintenance dose received was 800 mg twice a day
and the largest treatment duration was 5 days. Doses in children were derived from adult
doses and adjusted for body weight [7–9].
Overall, the JIKI trial results showed that mortality was strongly associated with baseline
viremia. The results provided no evidence that favipiravir monotherapy at this dose might
have a favorable benefit/risk ratio in patients with very high viral load at onset, but that it
would merit future research in patients with a cycle threshold (Ct) 20, corresponding to a
viral load below 107.7 genome copies/mL [7]. We previously published the trial results without
reporting drug concentrations because they were not available at the time of the publication.
Here we report the results of the concentrations of favipiravir that were measured in
patients of the JIKI trial. We compare them to the concentrations predicted by the model
before the trial [8] and we analyse the possible association between drug plasma concentra-
tions, viral loads and biochemical/haematological parameters.
Methods
Ethics statement
Three ethics committees were approached, namely, the institutional review board of the Insti-
tut National de la Sante´ et de la Recherche Me´dicale (Inserm, France), the Me´decins Sans
Frontières International Ethics Committee, and the Guinean Comite´ National d’E´thique pour
la Recherche en Sante´. All three committees commented on the protocol and approved the
final version and further amendments. Even though not asked for formal approval, because it
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was neither the sponsor nor investigator of the study, the WHO Ethics Research Committee
received the trial protocol and provided important advice that helped improve it.
Patients
The design of the JIKI trial has been previously reported [7]. The inclusion criteria in the JIKI
trial were the following: age1 year, body weight10kg, EVD confirmed by positive RT-
PCR, no pregnancy, ability to take oral drug, oral or signed informed consent. In this PK sub-
study, we included only patients of the JIKI trial that did not receive convalescent plasma prior
to treatment, as we did for the main analysis [7], and who had at least one blood sample after
the first day of treatment with sufficient volume to assess the favipiravir concentration.
Treatment
All participants received standard of care and favipiravir. Favipiravir (Toyama-Chemical, 200
mg tablets) was given orally. The treatment started as soon as the consent was obtained (Day-
0) and was administered for ten days. The adult dose was 6,000 mg at Day-0 (first dose: 2,400
mg; second dose eight hours after the first dose: 2,400 mg; third dose eight hours after the sec-
ond dose: 1,200 mg) and 2,400 mg (1,200 mg every 12 hours) from day 1 to day 9. For children,
the dose was adjusted on body weight [9].
Drug concentration measurements
Blood samples were taken at Day-0 (baseline), Day-2, Day-4, end of symptoms, Day-14 and
Day-30. Favipiravir total concentration was measured at Day-2 and Day-4 from plasma or
serum samples collected less than one hour before the first favipiravir intake of the day, i.e.,
between 11 and 12 hours after the last drug intake.
All samples were immediately decanted. EDTA, heparin or dry tubes were divided into ali-
quots, frozen at -20˚C, and shipped to the INSERM Jean Me´rieux biosafety level 4 laboratory
in Lyon. In this laboratory, they were heated at 60˚C for one hour to inactivate EBOV then
refrozen (-20˚C) and transferred to another INSERM laboratory in Marseilles for the drug
concentration measurement, using a validated procedure (S1 Text). Previous study on plasma
samples collected in nonhuman primates has shown that the inactivation process by heating
did not significantly impact the quantification of plasma favipiravir concentrations (S2 Text).
Serum and plasma samples were analysed using the same assay technique that had been vali-
dated for plasma samples. Both types of concentrations were referred as plasma concentrations
in the following.
Virology
EBOV viraemia (molecular viral load) was immediately assessed at the onsite laboratories in
four centers of the JIKI trial using a semi-quantitative RT-PCR assay (RealStar Filovirus Screen
RT-PCR Kit 1.0, Altona Diagnostics). The results were expressed in terms of Ct, whose value is
inversely proportional to viral load. An increase of 3 units in Ct scale corresponds approxi-
mately to a 1-log decline in viral load, therefore Ct unit corresponds to log scale for the viremia
[7]. The Ct cut-off value for positivity was<40.
Biochemistry and haematology
Biochemical and haematological parameter assays were performed using either the Piccolo
Xpress (Abaxis) or the i-STAT (Abbott Laboratories) point-of-care system. We used here the
Favipiravir pharmacokinetics in Ebola-Infected patients
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results of the parameters that were available in most patients and were the most plausible to
affect the drug pharmacokinetics, namely creatinine, sodium, albumin and haemoglobin.
Mortality
All deaths during the trial were attributed to EVD and patients who were discharged were con-
sidered as patients who survived. Criteria for discharge were the absence of fever and signifi-
cant symptoms for four consecutive days, ability to feed and walk independently, and two
consecutive negative blood EBOV RT-PCR tests [7].
Statistical methodology
Descriptive analysis of favipiravir concentrations. Descriptive statistics (median, min-
max) of concentrations measured at Day-2 and Day-4 were performed. In patients having
both measurements at Day-2 and Day-4, the change in concentrations was calculated. A Wil-
coxon signed-rank test was performed to assess any significant change.
Model-based analysis for the evolution of favipiravir concentrations. In order to adjust
for the variability due to individual characteristics, deviation in the dosing regimen or in the
sampling times, we calculated for each observation the predicted concentration using the phar-
macokinetic model provided by the manufacturer by accounting in each patient for i) the age
and weight ii) the dosing regimen iii) the sampling times of drug measurements. As the drug
sampling measurement was done within the hour preceding the morning dose and the exact
sampling time was not reported, we assumed that blood collection was done 30 minutes before
the next drug intake. The predicted concentrations on Day-2 and Day-4 were then compared
to the observations at Day-2 and Day-4, respectively, using a Wilcoxon signed-rank test. In
patients having concentrations at both Day-2 and Day-4, a Wilcoxon test for paired values was
also used to compare the change between Day-2 and Day-4 in the predicted and the observed
concentrations, respectively.
Drug concentrations and relationship with the virological response and mortality.
Correlations between the observed concentrations at Day-2 and Day-4, respectively, and the
corresponding increase in Ct value from baseline (equivalent to a decline in viral load) were
tested using a Spearman rank correlation test. A Ct value above 40 was treated as equal to 40.
The relationship between the observed concentrations at Day-2 and Day-4, respectively, and
mortality was tested using a Wilcoxon test. Consistent with our previous findings [7], the anal-
ysis were stratified on the initial Ct value at inclusion (Ct< 20 and Ct 20), using a Benja-
mini-Hochberg multiple testing correction for the tests in the two groups.
Drug concentrations and relationship with the biochemical and haematological param-
eters. Correlations between the observed concentrations on Day-2 and Day-4, respectively,
and the corresponding levels of biochemical or haematological parameters were tested using a
Spearman rank correlation test. In patients having two concentrations, the correlation between
the change in drug concentrations and the change in biochemical or haematological parame-
ters was tested using a Spearman rank correlation test.
Results
Patient’s characteristics
Of the 126 patients included in the JIKI trial, 10 were not included in the PK sub-study because
they also received convalescent plasma. In addition, 21 patients died before the PK sampling
time at Day-2 and 29 patients did not have enough plasma sample volume for drug concentra-
tion measurement. Thus a total of 66 patients were analysed in the PK sub-study (see flowchart
Favipiravir pharmacokinetics in Ebola-Infected patients
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in Fig 1), out of which 46 survived and 20 died. The median time from favipiravir initiation to
death was 5 days (min-max: 2–17), with 8 patients who died between Day-2 and Day-4, 11
who died between Day-4 and Day-7 and one who died at Day-17. Patients took favipiravir as
per the protocol and two missed doses were reported, both occurring the first day of drug
initiation.
The characteristics of the patients included in the analysis are given in Table 1 and are com-
pared with those of patients included in the main analysis of the JIKI trial but not included in the
PK sub-study. The patients included in this sub-PK analysis had significantly higher Ct values,
lower creatinine, CRP values at baseline and significantly lower mortality rate than those who were
not included (30% vs 82%, p<10−7). This is due in particular to the fact that the 21 patients who
died before the PK sampling time at Day-2 could not be included in this sub-PK analysis (Fig 1).
Children and adolescents
Among the 66 patients included in the PK sub-study, there were five adolescents (14–17 years
old) and a 5-year old child. The child had a weight of 14 kg at inclusion and received 600/400/
200 mg at Day-0 followed by a maintenance dose of 200 mg thrice a day. He had negative
malaria test, initial EBOV Ct value of 19.9, initial EBOV viral load of 9.1 log10 copies/mL and
no biochemical or haematological parameters before or during treatment. Three adolescents,
aged 14, 14 and 17 and weighting 42, 31 and 48 kg, respectively, received loading doses of
1,600/1,600/800, 1,200/1,200/600 and 2,000/2,000/1,000 mg, respectively. Two adolescents,
aged 15 and 16 years and weighting more than 50 kg received the adult dose. Among these 6
patients, only the 15-year old adolescent did not survive the infection.
Drug concentrations
Overall, 94 favipiravir trough concentrations were collected, 44 at Day-2 and 50 at Day-4.
Among these 94 concentrations, 67 were obtained from plasma samples and 27 were from
serum samples, and concentration in plasma and serum samples were largely similar (S3
Text). The median sampling time for the Day-2 measurement was 2.6 days after treatment ini-
tiation (min-max: 1.6–2.9) and the median sampling time for the Day-4 measurement was 4.6
days after treatment initiation (3.3–7.6). At Day-2, the median observed trough concentration
was 46.1 μg/mL (23–106.9) and was close to the targeted trough concentration (57 μg/mL).
However the concentrations dropped at Day-4 and the median concentration was 25.9 μg/mL
Fig 1. Flowchart of the patients included in the PK analysis of the JIKI trial
doi:10.1371/journal.pntd.0005389.g001
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Table 1. Characteristics at inclusion of the 66 patients included and the 50 patients not included in the PK analysis of the JIKI trial.
Characteristics Patients included in PK
sub-study n = 66
Patients included in JIKI trial but not included in PK sub-study
and did not receive convalescent plasma n = 50
p-value§
Female sex 41 (62.1%) 28 (56.0%) 0.89
Age 33.5 (5–78) 28.0 (2–80) 0.07
 6 y 1 (1.5%) 11 (22.0%)
13 to 29 y 26 (39.0%) 16 (32.0%)
 30 y 39 (59.1%) 23 (46.0%)
Weight (kg) 55 (14–102), 5 NA 51 (10–86), 6 NA 0.06
Time from first symptoms to
admission (days)
4 (0–14) 3 (-1-14) 0.28
Symptoms prior to admission
Fever 61 (92.4%) 44 (88.0%) 0.42
Diarrhea 35 (53.0%) 18 (36.0%) 0.07
Nausea/vomiting 30 (45.5%) 23 (46.0%) 0.95
Hemorrhage 11 (16.7%) 4 (8.0%) 0.17
Hiccup 9 (13.6%) 9 (18.0%) 0.52
Extreme fatigue 61 (92.4%) 46 (92.0%) 0.93
Positive malaria rapid test 8 (12.1%) 12 (24.0%) 0.09
EBOV RT-PCR Ct value 22.6 (14.4–32.0), 1 NA 18.1 (12.3–28.4), 5 NA 3.9x10-7
< 20 19 (29.2%) 32 (71.1%)
 20 46 (70.7%) 13 (28.9%)
EBOV viral load (log10 copies/mL) 7.15 (3.40–9.23), 9 NA 8.56 (4.48–10.65), 16 NA 9.8x10-6
> 7.7 log10 copies/mL 18 (31.6%) 27 (79.4%)
 7.7 log10 copies/mL 39 (68.4%) 7 (20.6%)
Serum biochemistry
Creatinine (μmol/L) 114.9 (30.0–703.0), 6 NA 237.0 (31.0–1076.0), 7 NA 0.006
Creatinine < 110 μmol/L 28 (46.7%) 10 (21.3%)
Creatinine 110 to 299 μmol/L 24 (40.0%) 16 (34.0%)
Creatinine300 μmol/L 8 (13.3%) 17 (36.2%)
BUN (mmol/L) 7.0 (1.0–107.0), 7 NA 14.4 (1.1–60.0), 5 NA 0.002
BUN:creatinine ratio 0.06 (0.02–0.34), 7 NA 0.06 (0.03–0.27), 6 NA 0.53
Sodium (mmol/L) 132.0 (121.0–142.0), 12
NA
133.0 (124.0–143.0), 8 NA 0.1
Potassium (mmol/L) 3.9 (1.5–5.9), 13 NA 3.9 (2.5–6.7), 9 NA 0.08
Glucose (mmol/L) 5.8 (2.1–28.4), 14 NA 6.0 (1.5–14.7), 9 NA 0.71
AST (IU/L) 362.5 (28.0–2000.0), 28
NA
1008.0 (43.0–2000.0), 36 NA 0.21
ALT (IU/L) 126.0 (22.0–1356.0), 26
NA
362.5 (21.0–1698.0), 30 NA 0.03
ALT/AST ratio 0.31 (0.13–1.08), 28 NA 0.21 (0.10–0.69), 37 NA 0.04
CK (IU/L) 909.0 (109.0–5000.0), 27
NA
2038.0 (163.0–5000.0), 29 NA 0.27
Total bilirubin (μmol/L) 10.0 (0.5–19.0), 27 NA 13.0 (6.0–43.0), 30 NA 0.02
Amylase (IU/L) 92.0 (33.0–458.0), 26 NA 114.0 (24.0–434.0), 29 NA 0.66
CRP (mg/L) 15.1 (5.0–153.1), 28 NA 54.0 (11.6–200.0), 30 NA 0.0002
Albumin (g/L) 32.0 (25.0–40.0), 26 NA 29.0 (21.0–37.0), 29 NA 0.06
Haemoglobin (g/dL) 13.6 (10.2–16.7), 48 NA 15.3 (10.2–21.8), 27 NA 0.03
Time from first symptoms to favipiravir
initiation (days)
4.5 (0–15) 4.0 (0–15) 1.0
(Continued )
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(0–173.2) (Fig 2). This trend was observed in both plasma and serum samples (S3 Text). In
patients having measurements at Day-2 and Day-4, the median reduction was -19.8 μg/mL
(-54.6–-1.7) and was significantly different from 0 (p<10−5).
Model-based analysis
Next, we refined our comparisons by adjusting the model’s predictions for the individual
dosing regimen, sampling time, age and weight for the predicted concentrations (Fig 3 and
Table 2). In the 5 patients for whom the information was not available (Table 1), a weight
of 70 kg was assumed. At Day-2 the median observed concentration was equal to 46.1 μg/mL
and the median predicted concentration was equal to 54.3 μg/mL (p = 0.01). At Day-4, the
difference was more pronounced, with a median observed concentration of 25.9 μg/mL com-
pared to a median predicted concentration of 64.4 μg/mL (p<10−6). While the model pre-
dicted a modest median increase in concentrations equal to 5.1 μg/mL between Day-2 and
Day-4, the drug concentrations actually had a marked median decrease equal to -19.8 μg/mL
(p<10−8).
Relationship with virological response and mortality
One patient for whom no initial Ct value was available was not included in this sub-study and
two PK measurements did not have corresponding Ct values. Overall 65 patients with 90
simultaneous measurements of favipiravir concentrations and Ct values were included in the
analysis (41 and 49 observations at Day-2 and Day-4, respectively). Regardless of the day con-
sidered, no significant relationship between the EBOV viral decline in plasma (increase in Ct
value) and favipiravir concentrations could be established (Fig 4) and no significant associa-
tion between mortality and drug concentrations was found (Table 3).
Relationship with biochemical and haematological parameters
Longitudinal evolution of the biochemical and haematological parameters are displayed in S1
Fig. Albumin concentrations and haemoglobin levels decreased in most patients, while
median sodium increased over time. For creatinine levels, two patterns were observed: in most
patients, creatinine level decreased during treatment but in a subset of patients, creatinine
increased strongly over time (S1 Fig). We found no significant correlation between the drug
concentrations and any of the biochemical parameters at Day-2 or Day-4 (S2 Fig).
Table 1. (Continued)
Characteristics Patients included in PK
sub-study n = 66
Patients included in JIKI trial but not included in PK sub-study
and did not receive convalescent plasma n = 50
p-value§
IV fluid compensation 59 (89.4%) 45 (90.0%) 0.92
Time from favipiravir initiation to death
(days)
5 (2–17) 3 (0–7) 0.0003
Outcome 3.4x10-8
Died 20 (30.3%) 41 (82.0%)
Survived 46 (69.7%) 9 (18.0%)
Data are in n (percent) or median (min-max).
NA: missing values.
doi:10.1371/journal.pntd.0005389.t001
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Discussion
We reported here the favipiravir plasma concentrations obtained in 66 patients of the JIKI
trial. The main finding of our analysis was that favipiravir concentration was significantly
below but still close to the predicted value target concentration at Day-2, but decreased by
nearly 50% between Day-2 and Day-4. Consequently, the concentrations at Day-4, with a
median value of 25.9 μg/mL, were much below the predicted model-based value. With a pro-
tein binding of 54%, free favipiravir trough concentrations at Day-4 remained thus slightly
larger than the in vitro EC50 reported in Oestereich et al., which was estimated at 10.5 μg/mL
[4], but lower than those reported in another publication, where the EC50 of favipiravir was
found larger than 31 μg/mL[3]. The conclusion was similar when model predictions were
adjusted for individual dosing regimen or individual characteristics. In particular, these low
concentrations were not due to a lack of compliance, as only two doses were not taken and
Fig 2. Observed trough concentrations of favipiravir at Day-2 (n = 44) and Day-4 (n = 50) after
treatment initiation. Red points represent concentrations measured in patients who died during the trial,
green points represent concentrations measured in those who survived. Concentrations obtained in patients
receiving adult dose or weighted-based dose are presented in circles and stars, respectively. Lines connect
data obtained in the 28 patients who had both measurements at Day-2 and Day-4. Boxplots represent the
distribution of the concentrations. The lower and upper hinges correspond to the first and third quartiles. The
upper whisker extends from the hinge to the highest value that is within 1.5 * IQR of the hinge, where IQR is
the inter-quartile range, or distance between the first and third quartiles. The lower whisker extends from the
hinge to the lowest value within 1.5 * IQR of the hinge.
doi:10.1371/journal.pntd.0005389.g002
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both occurred on the first day of treatment initiation. Of note the assay technique was only val-
idated for plasma samples and we did not distinguish these two types of drug concentrations.
Yet serum and plasma are close matrices and similar values were observed in both plasma and
serum samples, including the strong reduction in drug concentrations between day 2 and
day 4 (S3 Text). Lastly, we did not find any significant correlation between the drug exposure
and the virological response. Taken together, these results indicate that it is possible that the
favipiravir concentrations in the JIKI trial were not sufficient to strongly inhibit the viral
replication.
Fig 3. Observed trough concentrations (y-axis) versus predicted trough concentrations (x-axis) at Day-2 (left, n = 44 observations)
and Day-4 (right, n = 50) after treatment initiation. Red points represent concentrations measured in patients who died during the trial,
green points represent concentrations measured in those who survived.
doi:10.1371/journal.pntd.0005389.g003
Table 2. Observed and adjusted predicted (from the pharmacokinetic model provided by the manufacturer) trough concentrations of favipiravir at
Day-2 and Day-4 in the 66 patients included in the PK analysis of the JIKI trial.
Number of patients Sampling time (days after treatment
initiation)
Favipiravir trough concentrations
Observed (μg/mL) Adjusted Predicted (μg/
mL)
p-value§
Day-2 44 2.6 (1.6–2.9) 46.1 (2.3–106.9) 54.3 (33.8–81.1) 0.012
Day-4 50 4.6 (3.3–7.6) 25.9 (0–173.2) 64.4 (36.7–89.7) <10−6
Day-4 minus Day-
2
28 -19.8 (-54.6–1.7) 5.1 (-3.2–26.6) <10−8
Day-4/Day-2 28 0.54 (0–1.11) 1.08 (0.94–1.79) <10−7
Data are in n or median (min-max).
§p-value of Wilcoxon paired test of the difference between observed and adjusted predicted concentrations.
doi:10.1371/journal.pntd.0005389.t002
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Yet this conclusion should be nuanced and taken cautiously for several reasons. First the
analysis relied only on plasma favipiravir concentrations and intracellular concentrations of
the active phosphorylated moiety were not available. For instance, intracellular concentrations
of HIV nucleotide reverse transcriptase inhibitors were associated with antiviral efficacy, but
not with the plasma concentrations of the corresponding nucleoside analogue [10]. Second
Fig 4. Difference in Ct values at Day-2 (left) or Day-4 (right) from baseline (the larger the value the larger the viral decline) versus
drug concentrations. Top: patients with a low baseline Ct value (Ct<20) (n = 15 and 12); bottom: patients with a high baseline Ct value
(Ct>=20) (bottom, n = 26 and 37). Red points represent concentrations measured in patients who died during the trial, green points represent
concentrations measured in those who survived. Triangles indicate Ct values that were above 40 (detection limit) and were treated as equal
to 40, and circles are observed values. Black lines are Loess trend lines.
doi:10.1371/journal.pntd.0005389.g004
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our analysis only relied on pre-dose concentrations but other PK factors that could not be
determined here (e.g., AUC, time above EC50 or EC99) could be a better marker of drug effi-
cacy. Third, the fact that no significant correlation was found between the drug exposure and
the virological response could also be due to the delay between infection and treatment initia-
tion. For instance viral dynamic modelling shows that a drug affecting viral replication, such
as favipiravir, will only have a limited impact on viraemia if treatment is initiated after the vir-
aemia peak, regardless of drug efficacy [11]. Lastly, our study included only patients with drug
measurements at Day-2 or after, which excluded the most severe patients who died before
Day-2. Thus the patients analysed here are not representative of the JIKI population study and
this is why they differed in terms of mortality, initial Ct, viral load or biochemical parameters
(Table 1).
Two non-exclusive explanations for the lower-than-predicted concentrations and the unex-
pected drop between Day-2 and Day-4 can be proposed, namely the effect of the disease/treat-
ment on the drug pharmacokinetics and the non-linear PK of favipiravir which has never been
documented at this dosing regimen.
Many disease symptoms can affect the drug pharmacokinetic processes and lead to reduced
concentrations. For instance reduced plasma favipiravir concentrations and altered kinetics of
absorption and elimination were observed in a hamster model of arenaviral haemorrhagic
fever [12]. Here in absence of frequent data points and historical data with the same dosing
regimen, the effect of the disease cannot be evaluated. Obviously, the disease symptoms such
as dehydration, diarrhoea, vomiting, and reduction of gut perfusion can hamper or modify
favipiravir absorption. Likewise, the disease symptoms could also affect the bioavailability and
the hepatic first pass, in particular through an increase in the activity of the main metabolic
enzyme of favipiravir (aldehyde oxidase) with temperature [13]. In the JIKI trial, only 30 epi-
sodes of vomiting were reported within 30 minutes of drug intake, which represent 2% of
the overall number of drug intakes during the trial [7]. Altered pharmacokinetics could also
involve the distribution volume of favipiravir, which may be increased in Ebola patients due
to treatment or to the disease itself and may explain at least in part the reduced plasma concen-
trations. Favipiravir’s apparent volume of distribution ranges from 15 to 20 L and is likely
restricted to vascular and extra vascular fluids [5,6]. This distribution volume can be influ-
enced by two factors, namely change in volume of body fluid and/or favipiravir protein bind-
ing. In this sub-study of the JIKI trial, 89.4% of patients received IV fluid rehydration during
treatment [7], which may be responsible for haemodilution. Here, the modest decline in hae-
moglobin does not suggest a massive haemodilution but some vascular leakage resulting from
infusion of a large volume of rehydration fluid [14] or from the disease [15] cannot be ruled
out and could affect to some extent the favipiravir volume of distribution. However, such
Table 3. Observed trough concentrations of favipiravir at Day-2 and Day-4 in patients who died and those who survived according to the initial
baseline EBOV viral load.
Trough concentrations at Day-2 Trough concentrations at Day-4
Died Survived p-value§ Died Survived p-value§
All patients 41.1 (7.7–106.9), n = 16 46.4 (2.3–83.4), n = 27 0.52 27.8 (0.1–104.0), n = 10 24.6 (2.5–173.2), n = 39 0.20
Baseline Ct value 20 19.4 (7.7–79.3), n = 4 51.4 (2.3–83.4), n = 24 0.36 66.6 (0.1–99.3), n = 3 26.6 (2.7–173.2), n = 34 0.49
Baseline Ct value < 20 51.0 (7.8–106.9), n = 12 12.0 (11.9–58.0), n = 3 0.23 27.2 (21.2–104.0), n = 7 8.2 (2.5–31.2), n = 5 0.11
Data are in median (min-max).
§p-value calculated using Wilcoxon test to compare concentrations in patients who died and who survived. For two sub-group analysis, the threshold for
significativity after Benjamini-Hochberg correction is 0.025 for the most significant p-value and 0.05 for the second p-value.
doi:10.1371/journal.pntd.0005389.t003
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effects of infusion or disease are unlikely to solely explain the 50% reduction of favipiravir con-
centrations at Day-4 which would require a doubled volume of distribution. Another possible
alteration of the drug PK might be due to the reduction in albumin concentrations. With a
protein binding of 54%, a mean decline of about 20% in albumin levels between Day-0 and
Day-4 observed in this study is unlikely to have a major effect on favipiravir distribution or
elimination. Lastly, liver failure could impact favipiravir concentrations [16,17] but this should
rather favour drug accumulation than accelerate elimination. Of note, no significant correla-
tion was found between biochemical and haematological parameters and drugs concentrations
but the number of observations available was limited (S2 Fig).
The other main cause of these lower-than-predicted concentrations could be the fact that
the model used to predict the drug exposure in the JIKI trial was based on data collected in a
very different context. Indeed, the drug was historically developed against influenza virus and
the model was therefore developed using data collected with much lower doses of favipiravir
(at most 800 mg BID) for shorter period of time (at most 5 days). Favipiravir is known to have
non-linear pharmacokinetics due to its inhibitory effect on its main metabolic enzyme, alde-
hyde oxidase [5,6], which is also known to have several genetic polymorphisms with different
catalytic activities [18]. The fact that the non-linearity of favipiravir pharmacokinetics was
evaluated at doses much lower than those used in the JIKI trial [5] and that only few data on
patients of African ethnicity were previously available made it complicated to predict the expo-
sure of favipiravir with high doses in the JIKI study population. In addition, reduction in the
drug concentrations over 14 days of treatment was also observed in uninfected non-human
primates receiving high doses of favipiravir [19], suggesting that reduction in drug concentra-
tions over time may be an unanticipated feature of the drug that is independent of the disease
[19].
In conclusion, we have demonstrated that favipiravir plasma concentrations decreased with
time and were likely too low in most patients. We advocate for a dose-ranging study on healthy
volunteers to assess the pharmacokinetics and the tolerance of higher dosing regimen.
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